Tags

Type your tag names separated by a space and hit enter

[Novel treatment of bronchial asthma: application of leukotriene receptor antagonists and leukotriene synthesis inhibitors].
Ned Tijdschr Geneeskd. 1998 Jan 10; 142(5):72-8.NT

Abstract

Leukotrienes are important mediators of asthma. Antileukotriene therapy appears to provide the answer, owing to its reliever and controller properties. Two major categories of antileukotriene drugs have been introduced: leukotriene receptor antagonists and leukotriene biosynthesis inhibitors. Both types of drugs provide comparable protection against bronchoactive stimuli (allergen, exercise, aspirin). Moreover, beneficial effects have been observed in the treatment of day-to-day asthma, resulting in amelioration of clinical symptoms and lung function parameters, with reduction of beta2-agonist and corticosteroid use, suggesting antiinflammatory effects. Owing to these properties in combination with generally mild adverse effects, antileukotrienes are promising in the treatment of patients, including children with various forms of asthma. However, their definitive place in the asthma management will depend on the long-term effects on the chronic airway inflammation, which determines the structural changes within the airways, and the subsequent severity of clinical symptoms.

Authors+Show Affiliations

Academisch Ziekenhuis Rotterdam-Dijkzigt, Interne Geneeskunde I, Rotterdam. mw.dr.Z.DiamantNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

dut

PubMed ID

12013053

Citation

Diamant, Z, and P J. Sterk. "[Novel Treatment of Bronchial Asthma: Application of Leukotriene Receptor Antagonists and Leukotriene Synthesis Inhibitors]." Nederlands Tijdschrift Voor Geneeskunde, vol. 142, no. 5, 1998, pp. 72-8.
Diamant Z, Sterk PJ. [Novel treatment of bronchial asthma: application of leukotriene receptor antagonists and leukotriene synthesis inhibitors]. Ned Tijdschr Geneeskd. 1998;142(5):72-8.
Diamant, Z., & Sterk, P. J. (1998). [Novel treatment of bronchial asthma: application of leukotriene receptor antagonists and leukotriene synthesis inhibitors]. Nederlands Tijdschrift Voor Geneeskunde, 142(5), 72-8.
Diamant Z, Sterk PJ. [Novel Treatment of Bronchial Asthma: Application of Leukotriene Receptor Antagonists and Leukotriene Synthesis Inhibitors]. Ned Tijdschr Geneeskd. 1998 Jan 10;142(5):72-8. PubMed PMID: 12013053.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Novel treatment of bronchial asthma: application of leukotriene receptor antagonists and leukotriene synthesis inhibitors]. AU - Diamant,Z, AU - Sterk,P J, PY - 2002/5/16/pubmed PY - 2002/5/29/medline PY - 2002/5/16/entrez SP - 72 EP - 8 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 142 IS - 5 N2 - Leukotrienes are important mediators of asthma. Antileukotriene therapy appears to provide the answer, owing to its reliever and controller properties. Two major categories of antileukotriene drugs have been introduced: leukotriene receptor antagonists and leukotriene biosynthesis inhibitors. Both types of drugs provide comparable protection against bronchoactive stimuli (allergen, exercise, aspirin). Moreover, beneficial effects have been observed in the treatment of day-to-day asthma, resulting in amelioration of clinical symptoms and lung function parameters, with reduction of beta2-agonist and corticosteroid use, suggesting antiinflammatory effects. Owing to these properties in combination with generally mild adverse effects, antileukotrienes are promising in the treatment of patients, including children with various forms of asthma. However, their definitive place in the asthma management will depend on the long-term effects on the chronic airway inflammation, which determines the structural changes within the airways, and the subsequent severity of clinical symptoms. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/12013053/[Novel_treatment_of_bronchial_asthma:_application_of_leukotriene_receptor_antagonists_and_leukotriene_synthesis_inhibitors]_ L2 - https://www.diseaseinfosearch.org/result/633 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.